597,396 results
Search Results
2. Chronic pancreatitis for the clinician. Part 2: Treatment and follow-up. Interdisciplinary position paper of the Societat Catalana de Digestologia and the Societat Catalana de Pàncrees
- Author
-
Xavier Molero, Àngels Ginès, Lucas Ilzarbe, Teresa Serrano, Juli Busquets, Anna Casteràs, Carme Loras, Juan Ramón Ayuso, Gloria Fernàndez Esparrach, Mar Concepción, Esther Fort, Silvia Salord, Jorge J. Olsina, Miquel Masachs, Borobia Fg, Xavier Merino, Eva Cristina Vaquero, Joaquim Balsells, Jaume Boadas, Valentí Puig-Diví, and Míriam Cuatrecasas
- Subjects
Abdominal pain ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Exocrine pancreatic insufficiency ,Interventional radiology ,General Medicine ,Evidence-based medicine ,medicine.disease ,Genetic mutations ,Therapeutic approach ,Diabetes mellitus ,Quality of life (healthcare) ,Health care ,medicine ,Pancreatitis ,Position paper ,Intensive care medicine ,business ,Chronic pancreatitis - Abstract
Chronic pancreatitis is associated with impaired quality of life, high incidence of comorbidities, serious complications and mortality. Healthcare costs are exorbitant. Some medical societies have developed guidelines for treatment based on scientific evidence, but the gathered level of evidence for any individual topic is usually low and, therefore, recommendations tend to be vague or weak. In the present position papers on chronic pancreatitis from the Societat Catalana de Digestologia and the Societat Catalana de Pàncrees we aimed at providing defined position statements for the clinician based on updated review of published literature and on multidisciplinary expert agreement. The final goal is to propose the use of common terminology and rational diagnostic/therapeutic circuits based on current knowledge. To this end 51 sections related to chronic pancreatitis were reviewed by 21 specialists from 6 different fields to generate 88 statements altogether. Statements were designed to harmonize concepts or delineate recommendations. Part 2 of these paper series discuss topics on treatment and follow-up. The therapeutic approach should include assessment of etiological factors, clinical manifestations and complications. The complexity of these patients advocates for detailed evaluation in multidisciplinary committees where conservative, endoscopic, interventional radiology or surgical options are weighed. Specialized multidisciplinary units of Pancreatology should be constituted. Indications for surgery are refractory pain, local complications, and suspicion of malignancy. Enzyme replacement therapy is indicated if evidence of exocrine insufficiency or after pancreatic surgery. Response should be evaluated by nutritional parameters and assessment of symptoms. A follow-up program should be planned for every patient with chronic pancreatitis. © 2021 Elsevier España, S.L.U.
- Published
- 2022
3. Management of Incidental Thyroid Nodules on Chest CT: Using Natural Language Processing to Assess White Paper Adherence and Track Patient Outcomes
- Author
-
Benjamin Wildman-Tobriner, Steven Dondlinger, and Ryan G. Short
- Subjects
Thyroid nodules ,Chest ct ,Thyroid ultrasound ,computer.software_genre ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,White paper ,Chart review ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Thyroid Nodule ,Natural Language Processing ,Retrospective Studies ,Incidental Findings ,business.industry ,Ultrasound ,Nodule (medicine) ,medicine.disease ,030220 oncology & carcinogenesis ,Artificial intelligence ,medicine.symptom ,Tomography, X-Ray Computed ,business ,computer ,Natural language processing - Abstract
Objective The purpose of this study was to develop a natural language processing (NLP) pipeline to identify incidental thyroid nodules (ITNs) meeting criteria for sonographic follow-up and to assess both adherence rates to white paper recommendations and downstream outcomes related to these incidental findings. Methods 21583 non-contrast chest CT reports from 2017 and 2018 were retrospectively evaluated to identify reports which included either an explicit recommendation for thyroid ultrasound, a description of a nodule ≥ 1.5 cm, or description of a nodule with suspicious features. Reports from 2018 were used to train an NLP algorithm called fastText for automated identification of such reports. Algorithm performance was then evaluated on the 2017 reports. Next, any patient from 2017 with a report meeting criteria for ultrasound follow-up was further evaluated with manual chart review to determine follow-up adherence rates and nodule-related outcomes. Results NLP identified reports with ITNs meeting criteria for sonographic follow-up with an accuracy of 96.5% (95% CI 96.2-96.7) and sensitivity of 92.1% (95% CI 89.8-94.3). In 10006 chest CTs from 2017, ITN follow-up ultrasound was indicated according to white paper criteria in 81 patients (0.8%), explicitly recommended in 46.9% (38/81) of patients, and obtained in less than half of patients in which it was appropriately recommended (17/35, 48.6%). Discussion NLP accurately identified chest CT reports meeting criteria for ITN ultrasound follow-up. Radiologist adherence to white paper guidelines and subsequent referrer adherence to radiologist recommendations showed room for improvement.
- Published
- 2022
4. Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?
- Author
-
Naruto Taira, Kojiro Shimozuma, Takashi Fukuda, Takuya Kawahara, Takeru Shiroiwa, Shinichi Noto, Yasuhiro Hagiwara, Tetsuya Iwamoto, and Keiko Konomura
- Subjects
medicine.medical_specialty ,business.industry ,Health Policy ,Health Status ,Cancer ,Paper based ,medicine.disease ,Outcome (game theory) ,Eortc qlq c 30 ,Hospitals ,law.invention ,Randomized controlled trial ,Quality of life ,law ,Neoplasms ,Surveys and Questionnaires ,Physical therapy ,Quality of Life ,Medicine ,Humans ,Patient-reported outcome ,Patient Reported Outcome Measures ,Electronics ,business - Abstract
Purpose This study aimed to determine whether continual electronic patient-reported outcome (ePRO) measurements at home can capture the fluctuations in health-related quality of life (HRQOL) scores between visits. Methods We performed a randomized controlled trial to compare the scores obtained by standard practice (paper-based measurements in the hospital) to scores by continuous measurement of ePRO at home. Metastatic cancer patients were randomly assigned to either the paper-based ( n = 50) or the ePRO group ( n = 52). EQ-5D-5L and EORTC QLQ C-30 scores were obtained on 3 different chemotherapy days in the paper-based group. Meanwhile, scores were obtained on the chemotherapy day and on days 3, 7, 10, and 14 in the ePRO group during 2 cycles. The first hypothesis of our study was that both scores at the same time points would be equivalent despite different measurement frequency, place, or mode of measurement. The second hypothesis was that PRO score–adjusted time would be different between the groups. For equivalence, the endpoint was the mean EQ-5D-5L index value on the chemotherapy day before the outpatient treatment. Only if equivalence was shown, quality-adjusted life-days (QALDs) were considered using all the data. Results The adjusted mean difference in the EQ-5D-5L index was determined to be −0.013 (95% confidence interval [CI]: −0.049 to 0.022); the 95% CI did not exceed the equivalence margin. Similarly, the mean difference in global health status (2.28 [95% CI: −2.55 to 7.11]) also showed equivalence. However, the QALD by EQ-5D-5L was significantly lower in the ePRO group by 1.36 per 30 d (95% CI: −2.22 to −0.51; P = 0.0021). Conclusions Continual measurements of the HRQOL at home by ePRO may yield more detailed profiles of the HRQOL.
- Published
- 2022
5. White paper on antimicrobial stewardship in solid organ transplant recipients
- Author
-
Deborah Levine, Michael Spinner, Margaret R. Jorgenson, Jennifer Pisano, Dilek Ince, Helen S. Te, Sarah Kabbani, Miranda So, Stephanie M Pouch, Gopi Patel, Darshana Dadhania, Elizabeth C. Verna, Shahid Husain, Jonathan Hand, Linda Ohler, Graeme Forrest, Erika D. Lease, Lilian M. Abbo, Monica I. Ardura, Rachel Bartash, and Jeffrey D. Edelman
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Risk of infection ,MEDLINE ,Immunosuppression ,Organ Transplantation ,Tissue Donors ,Transplant Recipients ,United States ,Article ,Anti-Bacterial Agents ,Antimicrobial Stewardship ,White paper ,medicine ,Humans ,Immunology and Allergy ,Antimicrobial stewardship ,Pharmacology (medical) ,Stewardship ,Antibiotic prophylaxis ,Solid organ transplantation ,Intensive care medicine ,business - Abstract
Antimicrobial stewardship programs (ASPs) have made immense strides in optimizing antibiotic, antifungal, and antiviral use in clinical settings. However, although ASPs are required institutionally by regulatory agencies in the United States and Canada, they are not mandated for transplant centers or programs specifically. Despite the fact that solid organ transplant recipients in particular are at increased risk of infections from multidrug-resistant organisms, due to host and donor factors and immunosuppressive therapy, there currently are little rigorous data regarding stewardship practices in solid organ transplant populations, and thus, no transplant-specific requirements currently exist. Further complicating matters, transplant patients have a wide range of variability regarding their susceptibility to infection, as factors such as surgery of transplant, intensity of immunosuppression, and presence of drains or catheters in situ may modify the risk of infection. As such, it is not feasible to have a “one-size-fits-all” style of stewardship for this patient population. The objective of this white paper is to identify opportunities, risk factors, and ASP strategies that should be assessed with solid organ transplant recipients to optimize antimicrobial use, while producing an overall improvement in patient outcomes. We hope it may serve as a springboard for development of future guidance and identification of research opportunities.
- Published
- 2022
6. The palliative clinical specialist radiation therapist: A CAMRT White Paper
- Author
-
Nicole Harnett, Natalie Rozanec, and Carrie Lavergne
- Subjects
medicine.medical_specialty ,Radiological and Ultrasound Technology ,Palliative Radiation Therapy ,business.industry ,Radiation Therapist ,media_common.quotation_subject ,medicine.medical_treatment ,food and beverages ,Cancer ,medicine.disease ,Radiation therapy ,White paper ,Health care ,medicine ,Radiology, Nuclear Medicine and imaging ,Quality (business) ,Incurable cancer ,Intensive care medicine ,business ,media_common - Abstract
Palliative radiation therapy (pRT) is an effective tool for people with incurable cancer, in the treatment of many cancer-related symptoms such as pain, bleeding and dyspnea. As utilization rates for palliative radiation therapy increase, the demands on the healthcare system continue to grow. Radiation Therapists with advanced knowledge, skills and judgements began demonstrating their ability to practice autonomously in 2004, with the development of the Clinical Specialist Radiation Therapist (CSRT) role. Since this time, CSRTs with a specific focus in pRT (pCSRT) have been increasing in both numbers as well as their positive effects on the cancer care system. Integrating a pCSRT into the existing pRT system has resulted in increased access to and quality of pRT being delivered to palliative cancer patients. The benefits of the addition of pCSRTs to the cancer care system include increasing system capacity and increasing quality of care. This white paper provides information related to the improvements that can be realized in a RT program related to the care and treatment of its palliative patients by adding a pCSRT to the interprofessional healthcare team and suggest it as one of many strategies that can be undertaken to make improvements to access and quality of care.
- Published
- 2021
7. Diagnostic approach to neonatal and infantile cholestasis: A position paper by the SIGENP liver disease working group
- Author
-
Maurizio Fuoti, Mara Cananzi, Giulia Paolella, Manila Candusso, Paola Francalanci, Lidia Monti, Emanuele Nicastro, Lorenzo D'Antiga, Carlo Dionisi Vici, Michele Pinon, Lorenza Matarazzo, Irene Degrassi, P. Gaio, Angelo Di Giorgio, Giusy Ranucci, Pier Luigi Calvo, Giuseppe Indolfi, Claudia Mandato, Fabio Mosca, Pietro Vajro, Maria Pia Bondioni, Maria Iascone, Maria Grazia Clemente, Federica Nuti, Marco Sciveres, Jean de Ville de Goyet, Claudia Della Corte, Marco Spada, Chiara Grimaldi, Federica Ferrari, Gabriella Nebbia, Giuseppe Maggiore, Fabio Fusaro, Daniele Serranti, Daniele Alberti, Fabiola Di Dato, Paola Roggero, Raffaele Iorio, and Giovanni Boroni
- Subjects
Male ,medicine.medical_specialty ,Genetic liver disease ,Alagille syndrome ,Biliary atresia ,Diagnosis ,Inborn errors of metabolism ,Jaundice ,Monogenic liver disease ,Newborn ,Female ,Gastroenterology ,Humans ,Infant ,Infant, Newborn ,Cholestasis ,Evidence-Based Medicine ,Infant, Newborn, Diseases ,Practice Guidelines as Topic ,Diseases ,Disease ,Liver disease ,Epidemiology ,medicine ,Intensive care medicine ,Hepatology ,business.industry ,medicine.disease ,Etiology ,Position paper ,medicine.symptom ,business - Abstract
Neonatal and infantile cholestasis (NIC) can represent the onset of a surgically correctable disease and of a genetic or metabolic disorder worthy of medical treatment. Timely recognition of NIC and identification of the underlying etiology are paramount to improve outcomes. Upon invitation by the Italian National Institute of Health (ISS), an expert working grouped was formed to formulate evidence-based positions on current knowledge about the diagnosis of NIC. A systematic literature search was conducted to collect evidence about epidemiology, etiology, clinical aspects and accuracy of available diagnostic tests in NIC. Evidence was scored using the GRADE system. All recommendations were approved by a panel of experts upon agreement of at least 75% of the members. The final document was approved by all the panel components. This position document summarizes the collected statements and defines the best-evidence diagnostic approach to cholestasis in the first year of life.
- Published
- 2022
8. Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay
- Author
-
Liding Zhang, Xiaohan Liang, Yanqing Li, Haiming Luo, Xuewei Du, Shiqi Niu, and Ying Su
- Subjects
Paper ,Pathology ,medicine.medical_specialty ,Gold nanoparticle ,medicine.drug_class ,Point-of-care testing ,Biomedical Engineering ,Pharmaceutical Science ,Medicine (miscellaneous) ,Bioengineering ,Monoclonal antibody ,Applied Microbiology and Biotechnology ,Mice ,Cerebrospinal fluid ,Alzheimer Disease ,Limit of Detection ,medicine ,Quantitative assessment ,Medical technology ,Animals ,Humans ,R855-855.5 ,Immunoassay ,Amyloid beta-Peptides ,business.industry ,Aβ42 monomer ,Research ,Antibodies, Monoclonal ,Paper based ,Aβ42 oligomer ,Peptide Fragments ,Visual detection ,Blood ,Point-of-Care Testing ,Elisa test ,Paper-based lateral flow immunoassay ,Magnetic nanoparticles ,Molecular Medicine ,business ,Alzheimer’s disease ,Biomarkers ,TP248.13-248.65 ,Lateral flow immunoassay ,Biotechnology - Abstract
Aβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical Abstract
- Published
- 2021
9. Vaccination against COVID-19 for patients with primary immunodeficiency and hereditary angioedema: the position paper of the Russian Association of Allergology, Clinical Immunology, and the National Association of Experts in Primary Immunodeficiencies
- Author
-
Elena A. Latysheva, Anna Shcherbina, Tatiana V. Latysheva, Musa R. Khaitov, Daria Fomina, Natalya I. Ilyina, Evgeniya V. Nazarova, Irina Kondratenko, and Irina A. Manto
- Subjects
Pediatrics ,medicine.medical_specialty ,Angioedema ,business.industry ,Context (language use) ,General Medicine ,medicine.disease ,medicine.disease_cause ,Vaccination ,Hereditary angioedema ,Pandemic ,Primary immunodeficiency ,Medicine ,Position paper ,medicine.symptom ,business ,Coronavirus - Abstract
Since the end of 2019, the whole world has been seized by the COVID-19 pandemic caused by the SARS-CoV2 virus. To date, the infection has led to more than 4 million deaths worldwide, and to more than 140 thousand deaths in Russia. COVID-19 (abbreviation for COronaVIrus Disease 2019) is a potentially severe acute respiratory infection caused by the SARS-CoV-2 coronavirus (2019-nCoV). Vaccination against COVID-19 plays a key role in stopping the pandemic. According to existing experience in infections prevention, mass vaccination will reduce the virus’s expansion and the risk of vaccine-resistant strains’ development. In the context of the COVID-19 the question of the feasibility and safety of vaccination of patients with Primary Immunodeficiency and Hereditary Angioedema arises. The Russian Association of Allergists and Clinical Immunologists and the National Association of Experts in Primary Immunodeficiencies have developed and approved a position paper on vaccination of patients with Primary Immunodeficiency and Hereditary Angioedema against COVID-19. This position paper provides answers to key questions regarding the vaccination of patients with these diseases.
- Published
- 2021
10. Recommendations for photoprotection of parenteral nutrition for premature infants: An ASPEN position paper
- Author
-
Austin Michalski, Liliia Gutsul, Phil Ayers, Gordon S. Sacks, Daniel T. Robinson, Barbara Fleming, Beverly Holcombe, and Kathleen M. Gura
- Subjects
Parenteral Nutrition ,medicine.medical_specialty ,Medicine (miscellaneous) ,Infant, Premature, Diseases ,Health outcomes ,Patient safety ,Enteral Nutrition ,medicine ,Humans ,Child ,Intensive care medicine ,Bronchopulmonary Dysplasia ,Nutrition and Dietetics ,business.industry ,Infant, Newborn ,Infant ,Retinopathy of prematurity ,medicine.disease ,United States ,Parenteral nutrition ,Bronchopulmonary dysplasia ,Photoprotection ,Necrotizing enterocolitis ,Position paper ,business ,Infant, Premature - Abstract
Although crucial in improving health outcomes in the preterm infants, parenteral nutrition (PN) is not without risk, especially if handled improperly. A growing body of evidence suggests that components of PN admixtures, including lipid injectable emulsions (ILEs), are susceptible to degradation, including oxidation when exposed to light (ie, photo-oxidation), resulting in the production of reactive oxygen species. Infants, especially those born preterm, are considered more susceptible to consequences of oxidative stress than children and adults. Oxidative stress is associated with bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and intestinal failure-associated liver disease. The American Society for Parenteral and Enteral Nutrition (ASPEN) assembled a working group to provide recommendations on clinical practice surrounding photoprotection of PN.This Position Paper reviews the scientific literature on the formation of quantifiable peroxides and other degradation products when PN admixtures and ILEs are exposed to light and reports adverse clinical outcomes in premature infants exposed to PN. Recommendations for photoprotection of PN admixtures and ILEs are provided, as well as the challenges in achieving complete photoprotection with the equipment, supplies, and materials currently available in the US. ASPEN and the authors understand that the full implementation of complete photoprotection may not currently be feasible given current product availability; recommendations provided in this paper serve to represent the goal to which to strive as well as to highlight the importance of product availability to achieve these practices. This paper has been approved by the ASPEN Board of Directors.
- Published
- 2021
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.